Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amphastar Pharma (NQ: AMPH )

45.67 -0.22 (-0.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 310,276
Open 45.98
Bid (Size) 45.17 (5)
Ask (Size) 46.51 (1)
Prev. Close 45.89
Today's Range 45.55 - 46.35
52wk Range 26.76 - 46.86
Shares Outstanding 48,274,042
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90
On Tuesday, FibroGen stock saw a positive improvement to its Relative Strength Rating, rising to 94 from 90 a day earlier. 
Via Investor's Business Daily
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference
Via ACCESSWIRE

Performance

YTD
+61.95%
+61.95%
1 Month
+10.88%
+10.88%
3 Month
+27.82%
+27.82%
6 Month
+60.92%
+60.92%
1 Year
+51.28%
+51.28%

More News

Read More
Amphastar Pharma: Q1 Earnings Insights
Via Benzinga
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2023
Via ACCESSWIRE
Earnings Outlook For Amphastar Pharma
Via Benzinga
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2023
Via ACCESSWIRE
Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating
Via Investor's Business Daily
Lilly to Divest BAQSIMI to Amphastar
Via ACCESSWIRE
Why Shares of Amphastar Pharmaceuticals Rose Today
Via The Motley Fool
Earnings Outlook For Amphastar Pharmaceuticals
Via Benzinga
Eli Lilly Divests Low Blood Sugar Drug Baqsimi To Amphastar For $500M Cash
Via Benzinga
Amphastar Pharmaceuticals Business Update and Hold Conference Call on April 24th, 2023
Via ACCESSWIRE
Genmab Stock Hits 80-Plus Relative Strength Rating Benchmark
Via Investor's Business Daily
Amphastar Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
Via ACCESSWIRE
Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move
Via Benzinga
BioMarin Pharmaceutical Stock Shows Rising Relative Strength
Via Investor's Business Daily
Alkermes Stock Sees Rising Relative Strength Rating
Via Investor's Business Daily
Exelixis Stock Shows Rising Relative Price Performance; Still Shy Of Key Benchmark
Via Investor's Business Daily
BioMarin Pharmaceutical Stock Sees IBD RS Rating Improve To 74
Via Investor's Business Daily
Exelixis Stock Generating Improved Relative Strength Rating
Via Investor's Business Daily
Vertex Pharmaceuticals Stock Gets Technical Rating Upgrade
Via Investor's Business Daily
Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg
Via ACCESSWIRE
Kala Pharmaceuticals Stock Showing Rising Market Leadership; Earns 83 RS Rating
Via Investor's Business Daily
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.